Established in 2010, this clinical laboratory was founded by a team of fully licensed experts dedicated to delivering high-quality diagnostic services in the Miami area.

With an average of 20 years of experience, their licensed testing personnel ensure every test meets the highest standards of accuracy and reliability. The laboratory’s management and technical teams are committed to providing fast, dependable, and professional service to healthcare providers and patients alike.

The lab is proudly enrolled in the College of American Pathologists (CAP) and American Association of Bioanalysts (AAB) proficiency testing programs, ensuring compliance with legal standards and maintaining exceptional testing reliability.

Their comprehensive test menu and reputation for precision, speed, and personalized care have fueled their expansion into additional counties. Referring providers enjoy access to a secure online portal, offering seamless management of HIPAA-compliant patient results.

SERVICES:
• Hematology.
• Chemistry.
• Immunology / Serology
• Microbiology
• Pathology / Histology

The global clinical laboratory services market size was estimated at USD 233.63 billion in 2024 and is projected to reach USD 286.77 billion by 2030, growing at a CAGR of 3.82% from 2025 to 2030. The market is witnessing growth due to factors such as the increasing burden of chronic diseases and the growing demand for early diagnostic tests.

An increase in disease prevalence and high demand for early disease diagnosis are expected to boost the market in the coming years. These factors have prompted market players to introduce innovative services to address the growing demand. The introduction of accurate and technologically advanced products, such as companion diagnostics, biochips, & microarrays, has increased the demand for early disease detection. Products such as companion diagnostics also reduce the overall healthcare cost by helping physicians identify the most suitable treatment option based on a patient's genetic makeup. Furthermore, the growing prevalence of target diseases, such as cardiovascular diseases and diabetes, is a high-impact market driver over the forecast period. Cardiovascular disease has become the most dominant cause of mortality and morbidity in the world over the past three decades. According to the WHO, by 2030, cardiovascular diseases are estimated to cause approximately 23.6 million deaths, mainly due to heart disease and stroke. Moreover, the global prevalence of diabetes is constantly increasing, creating a large patient pool for the clinical laboratory services industry.

Seller Support:

The Seller is willing to stay on for a mutually agreed upon timeframe for a smooth transition. Employees are also willing to stay employed by the new owner. An NDA must be signed by all interested parties. A resume and proof of funds must also be provided.